These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 2224374)

  • 21. A double-blind, controlled trial in primary care patients with generalized anxiety: a comparison between buspirone and oxazepam.
    Strand M; Hetta J; Rosen A; Sörensen S; Malmström R; Fabian C; Marits K; Vetterskog K; Liljestrand AG; Hegen C
    J Clin Psychiatry; 1990 Sep; 51 Suppl():40-5. PubMed ID: 2211567
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of buspirone, diazepam, and placebo in patients with chronic anxiety states.
    Olajide D; Lader M
    J Clin Psychopharmacol; 1987 Jun; 7(3):148-52. PubMed ID: 2885344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of buspirone in the treatment of opioid withdrawal.
    Buydens-Branchey L; Branchey M; Reel-Brander C
    J Clin Psychopharmacol; 2005 Jun; 25(3):230-6. PubMed ID: 15876901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy. Effects on withdrawal severity and outcome.
    Schweizer E; Rickels K; Case WG; Greenblatt DJ
    Arch Gen Psychiatry; 1991 May; 48(5):448-52. PubMed ID: 2021297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of buspirone as an antianxiety agent: buspirone and diazepam versus placebo.
    Pecknold JC; Matas M; Howarth BG; Ross C; Swinson R; Vezeau C; Ungar W
    Can J Psychiatry; 1989 Nov; 34(8):766-71. PubMed ID: 2684380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In-patient benzodiazepine withdrawal: comparison of fixed and symptom-triggered taper methods.
    McGregor C; Machin A; White JM
    Drug Alcohol Rev; 2003 Jun; 22(2):175-80. PubMed ID: 12850904
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [alpha-beta L-aspartate magnesium in treatment of chronic benzodiazepine abuse: controlled and double-blind study versus placebo].
    Hantouche EG; Guelfi JD; Comet D
    Encephale; 1998; 24(5):469-79. PubMed ID: 9850822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Comparison of 6 different methods for lorazepam withdrawal. A controlled study, hydroxyzine versus placebo].
    Lemoine P; Touchon J; Billardon M
    Encephale; 1997; 23(4):290-9. PubMed ID: 9417395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is imipramine or buspirone treatment effective in patients wishing to discontinue long-term benzodiazepine use?
    Sontheimer DL; Ables AZ
    J Fam Pract; 2001 Mar; 50(3):203. PubMed ID: 11252203
    [No Abstract]   [Full Text] [Related]  

  • 30. Benzodiazepine withdrawal.
    Br J Psychiatry; 1990 Nov; 157():777-8. PubMed ID: 2099768
    [No Abstract]   [Full Text] [Related]  

  • 31. A clinical trial of buspirone and diazepam in the treatment of generalized anxiety disorder.
    Ross CA; Matas M
    Can J Psychiatry; 1987 Jun; 32(5):351-5. PubMed ID: 3308052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of buspirone in smoking cessation: a placebo-controlled trial.
    Schneider NG; Olmstead RE; Steinberg C; Sloan K; Daims RM; Brown HV
    Clin Pharmacol Ther; 1996 Nov; 60(5):568-75. PubMed ID: 8941030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Controlled comparison of buspirone and oxazepam in generalized anxiety.
    Ansseau M; Papart P; Gérard MA; von Frenckell R; Franck G
    Neuropsychobiology; 1990-1991; 24(2):74-8. PubMed ID: 2134114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Double-blind, placebo-controlled trial of two doses of abecarnil for geriatric anxiety.
    Small GW; Bystritsky A
    J Clin Psychiatry; 1997; 58 Suppl 11():24-9. PubMed ID: 9363045
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Buspirone in the treatment of Generalized Anxiety Disorders].
    Rzewuska M; Sobucka K
    Psychiatr Pol; 1993; 27(5):545-61. PubMed ID: 8255947
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Profile of action of a novel 5-hydroxytryptamine1A receptor ligand E-4424 to inhibit aversive behavior in the mouse, rat and marmoset.
    Costall B; Domeney AM; Farre AJ; Kelly ME; Martinez L; Naylor RJ
    J Pharmacol Exp Ther; 1992 Jul; 262(1):90-8. PubMed ID: 1352556
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Buspirone in the management of major depression: a placebo-controlled comparison.
    Fabre LF
    J Clin Psychiatry; 1990 Sep; 51 Suppl():55-61. PubMed ID: 2211570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Withdrawal symptoms after six weeks' treatment with diazepam.
    Murphy SM; Owen RT; Tyrer PJ
    Lancet; 1984 Dec; 2(8416):1389. PubMed ID: 6150380
    [No Abstract]   [Full Text] [Related]  

  • 39. Predictors of long-term benzodiazepine abstinence in participants of a randomized controlled benzodiazepine withdrawal program.
    Voshaar RC; Gorgels WJ; Mol AJ; van Balkom AJ; Mulder J; van de Lisdonk EH; Breteler MH; Zitman FG
    Can J Psychiatry; 2006 Jun; 51(7):445-52. PubMed ID: 16838826
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Withdrawal reaction after long-term therapeutic use of benzodiazepines.
    Busto U; Sellers EM; Naranjo CA; Cappell H; Sanchez-Craig M; Sykora K
    N Engl J Med; 1986 Oct; 315(14):854-9. PubMed ID: 3092053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.